ZYUS Life Sciences (TSXV:ZYUS) Beneish M-Score: -3.53 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:ZYUS ZYUS Life Sciences Corp TSXV:ZYUS
16 GF Score
Price C$0.50
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Beneish M-Score?

ZYUS Life Sciences TSXV:ZYUS 16 Beneish M-Score is -3.53 as of Jul. 21, 2026. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 6 warning signs investors should review. Among 910 Drug Manufacturers companies, ZYUS Life Sciences ranks better than 91.54% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.53 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for ZYUS Life Sciences's Beneish M-Score or its related term are showing as below:

TSXV:ZYUS' s Beneish M-Score Range Over the Past 10 Years
Min: -5.61   Med: -3.6   Max: -0.08
Current: -3.53

During the past 5 years, the highest Beneish M-Score of ZYUS Life Sciences was -0.08. The lowest was -5.61. And the median was -3.60.

ZYUS Life Sciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Beneish M-Score Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 0.00 -4.66 0.00

ZYUS Life Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.52 -5.61 -3.53 0.00 0.00

TSXV:ZYUS vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZYUS Life Sciences Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's Beneish M-Score falls into.


TSXV:ZYUS
16GF Score
ZYUS Life Sciences Corp TSXV:ZYUS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZYUS Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ZYUS Life Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2648+0.528 * 2.4996+0.404 * 2.3744+0.892 * 0.8586+0.115 * 0.5804
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0148+4.679 * -1.833476-0.327 * 3.8342
=-10.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was C$0.34 Mil.
Revenue was 0.122 + 0.066 + 0.105 + 0.12 = C$0.41 Mil.
Gross Profit was 0.055 + -0.075 + -0.004 + 0.069 = C$0.05 Mil.
Total Current Assets was C$0.91 Mil.
Total Assets was C$4.67 Mil.
Property, Plant and Equipment(Net PPE) was C$3.63 Mil.
Depreciation, Depletion and Amortization(DDA) was C$2.20 Mil.
Selling, General, & Admin. Expense(SGA) was C$8.11 Mil.
Total Current Liabilities was C$16.40 Mil.
Long-Term Debt & Capital Lease Obligation was C$12.22 Mil.
Net Income was -3.062 + -9.724 + -3.624 + -4.424 = C$-20.83 Mil.
Non Operating Income was -0.004 + -4.559 + 0.035 + 0.05 = C$-4.48 Mil.
Cash Flow from Operations was -1.391 + -1.927 + -2.521 + -1.951 = C$-7.79 Mil.
 Total Receivables was C$0.31 Mil.
Revenue was 0.114 + 0.126 + 0.123 + 0.118 = C$0.48 Mil.
Gross Profit was 0.06 + -0.064 + 0.071 + 0.064 = C$0.13 Mil.
Total Current Assets was C$1.90 Mil.
Total Assets was C$12.49 Mil.
Property, Plant and Equipment(Net PPE) was C$10.44 Mil.
Depreciation, Depletion and Amortization(DDA) was C$2.93 Mil.
Selling, General, & Admin. Expense(SGA) was C$9.30 Mil.
Total Current Liabilities was C$12.36 Mil.
Long-Term Debt & Capital Lease Obligation was C$7.60 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.341 / 0.413) / (0.314 / 0.481)
=0.825666 / 0.652807
=1.2648

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.131 / 0.481) / (0.045 / 0.413)
=0.272349 / 0.108959
=2.4996

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.912 + 3.625) / 4.672) / (1 - (1.898 + 10.44) / 12.49)
=0.028896 / 0.01217
=2.3744

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.413 / 0.481
=0.8586

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.934 / (2.934 + 10.44)) / (2.203 / (2.203 + 3.625))
=0.219381 / 0.378003
=0.5804

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(8.105 / 0.413) / (9.302 / 0.481)
=19.624697 / 19.338877
=1.0148

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((12.222 + 16.401) / 4.672) / ((7.595 + 12.362) / 12.49)
=6.126498 / 1.597838
=3.8342

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-20.834 - -4.478 - -7.79) / 4.672
=-1.833476

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ZYUS Life Sciences has a M-score of -10.57 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.53 mean?
ZYUS Life Sciences (TSXV:ZYUS) has a Beneish M-Score of -3.53 as of Jul. 21, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #77 out of 910 companies in the Drug Manufacturers industry, placing it in the top 8.5%.
Is ZYUS Life Sciences' Beneish M-Score too high?
ZYUS Life Sciences' current Beneish M-Score is -3.53. Based on the distribution chart, ZYUS Life Sciences ranks #77 out of 910 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #77 out of 910 companies for Beneish M-Score. This places ZYUS Life Sciences in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current Beneish M-Score is -3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current Beneish M-Score of -3.53. The current Beneish M-Score is -3.53. ZYUS Life Sciences' overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current Beneish M-Score is -3.53 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZLSCF:USA
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score

Get the complete analysis for TSXV:ZYUS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.50
Price